A Phase 1/2 study of IDE196 in patients with solid tumors harboring GNAQ/11 mutations or PRKC fusions
Contact:
NCT Number:
Protocol:
AAAS4168
Study Status:
Active/Enrolling
Population:
Adult
Phase:
I/II
The purpose of this study is to evaluate the safety profile of IDE196 (an “investigational” drug), in enrolled subjects to find out if it is safe and possibly helpful in patients with certain cancers such as: metastatic uveal melanoma, cutaneous melanoma or colorectal cancer or cancers with mutations in genes called GNAQ, GNA11, or PRKC fusion. The study may last for approximately 25 months and your participation will depend on how well you tolerate the study drug and your overall condition during the study.
Are you Eligible? (Inclusion Criteria)
- Do you have a solid tumor(s) that has either progressed following prior standard therapies?
- Are you willing to possibly undergo biopsies during the study?
- Are you 18 years of age or older?
Specialty Area(s)
Bladder Cancer , Colon and Rectal Cancer, Cervical Cancer, Lung cancer, Ocular Melanoma, Pancreatic Cancer, Stomach Cancer, Precision Oncology, Immunotherapy
Principal Investigator
Trial Location(s)
CUIMC/Herbert Irving Pavilion
161 Fort Washington Avenue
New York, NY 10032
